Results showed that in GBMLGG (Glioma), BRCA, and PAAD, high expression of JAM-A was significantly related to poor OS of cancer patients, whereas in KIRC, high expression of JAM-A benefited patients’ survival (Figure 2A). This evidence concerns the gene F11R and cancer.